The ECFS-CTN cannot guarantee that the information provided here is comprehensive. Please go to the link for detailed and up-to-date information on study background, eligibility criteria, study design, outcome measures, study status, participating sites, sponsor contact information and timelines.

You can also contact the CTN coordinating centre for additional information: (link sends e-mail)

Study Name on (link is external)
A Phase 3 Rollover Study of Lumacaftor in Combination With Ivacaftor in Subjects 12 Years and Older With Cystic Fibrosis
Study DrugIvacaftor (VX-770)
Lumacaftor (VX-809)
Type of Study DrugCFTR Modulation
Study TitleA Phase 3, Rollover Study to Evaluate the Safety and Efficacy of Long-term Treatment With Lumacaftor in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mutation
Study Phase3
Study SponsorVertex

Link on (link is external) (link is external)

Participating ECFS-CTN sitesBelgium: Leuven
Czech Republic : Prague
Denmark : Copenhagen
France: Bordeaux, Toulouse, Strasbourg, Lyon, Marseille, Montpellier, Roscoff, Nantes, West-Paris, 
Germany : Berlin, Frankfurt, Hannover, Cologne, Munich
Italy: Florence, Genoa, Milan, Rome, Verona
The Netherlands: Rotterdam
Spain: Barcelona
Sweden: Gothenburg, Stockholm
UK: Belfast, Birmingham, Leeds, London, Nottingham
Age12 Years and older